Home/Rare Diseases/Dravet Syndrome

Neurological & Neuromuscular

Dravet Syndrome

Also called Severe Myoclonic Epilepsy of Infancy, SMEI

Dravet Syndrome represents one of the most severe forms of childhood-onset epilepsy, caused primarily by loss-of-function mutations in the SCN1A gene. This gene encodes the Nav1.

View active trialsMatch me to a trial

About Dravet Syndrome

Dravet Syndrome represents one of the most severe forms of childhood-onset epilepsy, caused primarily by loss-of-function mutations in the SCN1A gene. This gene encodes the Nav1.1 alpha subunit of voltage-gated sodium channels essential for neuronal excitability. The disease typically begins with a prolonged febrile seizure, often the first febrile convulsion the child experiences, occurring without warning during a fever. Initial seizures may respond to standard antiepileptic medications, but over months to years, seizures become increasingly frequent and refractory to treatment. Multiple seizure types develop, creating a complex clinical picture. Developmental progress, which may have appeared normal initially, plateaus or regresses. By school age, many children have significant intellectual disability. Behavioral problems including autism spectrum features, aggression, and hyperactivity frequently emerge. Sudden unexpected nocturnal death in epilepsy (SUDEP) represents a significant ongoing risk.

Common Symptoms

  • First seizures typically occur between 6 months and 3 years of age, often triggered by fever
  • Prolonged seizures lasting more than 30 minutes (febrile status epilepticus)
  • Multiple types of seizures: generalized tonic-clonic, myoclonic, atypical absence, and focal seizures
  • Developmental delay and intellectual disability
  • Speech and language difficulties
  • Behavioral and social challenges, including autism spectrum features

Who It Affects

Dravet Syndrome typically manifests between 6 months and 3 years of age, though most commonly around 6-12 months. It affects males and females equally across all ethnic and racial groups. About 80% of cases result from de novo (new) SCN1A mutations, though familial inheritance occurs in approximately 10-20% of cases, often with incomplete penetrance.

Getting Involved in Clinical Trials

Dravet Syndrome research is advancing with FDA-approved medications like stiripentol and cannabidiol showing efficacy, and ongoing trials investigating additional cannabinoid-based treatments, gene therapy approaches, and sodium channel modulators. Clinical trials are also exploring antisense oligonucleotides and other molecular approaches to restore SCN1A function. Specialized epilepsy centers often have access to clinical trial information and can assess eligibility. The Dravet Syndrome Foundation maintains resources on trial availability and treatment approaches.

Trusted Sources

Active Clinical Trials for Dravet Syndrome

Finding trials for Dravet Syndrome...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...